Yichen Zheng

Yichen Zheng

Auto-generated profile, based on publicly available information

Yichen Zheng

Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2023 in Cancer Communications
Verified
Journal Article
Open access
YZYichen Zheng
Yichen Zheng
LSLingqi Sun
Lingqi Sun
JGJiamin Guo
Jiamin Guo
JMJi Ma
Ji Ma
The advent of immunotherapy has significantly reshaped the landscape of cancer treatment, greatly enhancing therapeutic outcomes for multiple types of cancer. However, only a small subset of individuals respond to it, underscoring the urgent need for new methods to improve its response rate. Ferroptosis, a recently discovered form of programmed cell death, has emerged as a promising approach for anti‐tumor therapy, with targeting ferroptosis to kill tumors seen as a potentially effective strategy. Numerous studies suggest that inducing ferroptosis can synergistically enhance the effects of immunotherapy, paving the way for a promising combined treatment method in the future. Nevertheless, recent research has raised concerns about the potential negative impacts on anti‐tumor immunity as a consequence of inducing ferroptosis, leading to conflicting views within the scientific community about the interplay between ferroptosis and anti‐tumor immunity, thereby underscoring the necessity of a comprehensive review of the existing literature on this relationship. Previous reviews on ferroptosis have touched on related content, many focusing primarily on the promoting role of ferroptosis on anti‐tumor immunity while overlooking recent evidence on the inhibitory effects of ferroptosis on immunity. Others have concentrated solely on discussing related content either from the perspective of cancer cells and ferroptosis or from immune cells and ferroptosis. Given that both cancer cells and immune cells exist in the tumor microenvironment, a one‐sided discussion cannot comprehensively summarize this topic. Therefore, from the perspectives of both tumor cells and tumor‐infiltrating immune cells, we systematically summarize the current conflicting views on the interplay between ferroptosis and anti‐tumor immunity, intending to provide potential explanations and identify the work needed to establish a translational basis for combined ferroptosis‐targeted therapy and immunotherapy in treating tumors.


19 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJi Ma
Ji Ma
TWTao Wang
Tao Wang
YZYichen Zheng
Yichen Zheng
TRTonghui Ren
Tonghui Ren
DZDongdong Zhu
Dongdong Zhu
WWWentao Wang
Wentao Wang
Immune checkpoint inhibitors plus gemcitabine and cisplatin (GC) are standard first-line treatment for advanced biliary tract cancer (BTC). Here we report BicureX (ChiCTR2300073023), a single-centre, open-label, single-arm phase II trial of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, plus GC for unresectable locally advanced or metastatic BTC. Patients received up to eight combination cycles followed by cadonilimab maintenance. The primary endpoint was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1); secondary endpoints included disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Sixty-one patients were enrolled. At a median follow-up of 23.5 months, ORR was 55.7% (34/61; 95% confidence interval, 42.4–68.5%), meeting the prespecified Simon two-stage efficacy criterion. DCR was 85.2%, median DoR 6.1 months, PFS 8.0 months, and OS 15.6 months. Grade ≥3 adverse events (AEs) occurred in 68.9% and grade ≥3 immune-related adverse events (irAEs) in 18.0%; no death was adjudicated as treatment-related. Proteomics identified a post-hoc exploratory three-protein response-associated signal without significance after false discovery rate correction. These findings support further randomized evaluation.